ATE295362T1 - Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten - Google Patents
Chinazolone derivate als alfa 1a/b adrenozeptor antagonistenInfo
- Publication number
- ATE295362T1 ATE295362T1 AT01985417T AT01985417T ATE295362T1 AT E295362 T1 ATE295362 T1 AT E295362T1 AT 01985417 T AT01985417 T AT 01985417T AT 01985417 T AT01985417 T AT 01985417T AT E295362 T1 ATE295362 T1 AT E295362T1
- Authority
- AT
- Austria
- Prior art keywords
- chinazolone
- alfa
- derivatives
- adrenoceptor antagonists
- adrenoceptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25933701P | 2001-01-02 | 2001-01-02 | |
| US32526701P | 2001-09-27 | 2001-09-27 | |
| PCT/EP2001/014885 WO2002053558A1 (en) | 2001-01-02 | 2001-12-17 | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE295362T1 true ATE295362T1 (de) | 2005-05-15 |
Family
ID=26947245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01985417T ATE295362T1 (de) | 2001-01-02 | 2001-12-17 | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1363899B1 (de) |
| JP (1) | JP4031363B2 (de) |
| KR (1) | KR100554813B1 (de) |
| CN (1) | CN1237060C (de) |
| AR (1) | AR035775A1 (de) |
| AT (1) | ATE295362T1 (de) |
| BR (1) | BR0116662A (de) |
| CA (1) | CA2432578C (de) |
| DE (1) | DE60110844T2 (de) |
| ES (1) | ES2241891T3 (de) |
| MX (1) | MXPA03005854A (de) |
| PA (1) | PA8536001A1 (de) |
| PE (1) | PE20020735A1 (de) |
| UY (1) | UY27109A1 (de) |
| WO (1) | WO2002053558A1 (de) |
| ZA (1) | ZA200305038B (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| MXPA06000185A (es) * | 2003-07-02 | 2006-04-11 | Hoffmann La Roche | Derivados de quinazolinas 5-sustituidas. |
| WO2005005395A2 (en) | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
| WO2007028051A2 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
| UA92765C2 (ru) * | 2005-11-24 | 2010-12-10 | Киссеи Фармасьютикал Ко., Лтд. | Фармацевтическое средство для лечения уретеролитиаза |
| JP5396379B2 (ja) | 2007-04-02 | 2014-01-22 | エボテック・アーゲー | ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用 |
| WO2008130481A1 (en) | 2007-04-17 | 2008-10-30 | Renovis, Inc. | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| BRPI0812504B8 (pt) | 2007-06-21 | 2021-05-25 | Cara Therapeutics Inc | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| JO3156B1 (ar) | 2009-07-09 | 2017-09-20 | Novartis Ag | ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2015091795A1 (en) | 2013-12-20 | 2015-06-25 | Laboratorios Del Dr. Esteve S.A. | Fused imidazolyl derivatives, their preparation and use as medicaments |
| CN109843856B (zh) | 2016-05-18 | 2023-05-02 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
| CN107434786B (zh) * | 2016-05-27 | 2025-11-18 | 广东东阳光药业股份有限公司 | 苯并咪唑化合物及其制备方法 |
| AU2018260414A1 (en) | 2017-04-24 | 2019-10-17 | Novartis Ag | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| KR102861303B1 (ko) | 2017-11-15 | 2025-09-17 | 미라티 테라퓨틱스, 인크. | Ｋｒａｓ ｇ12ｃ 억제제 |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| KR102871791B1 (ko) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| EP3930845A1 (de) * | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclische heterocyclyl-verbindungen und ihre verwendung |
| CA3148745A1 (en) | 2019-08-29 | 2021-03-04 | Xiaolun Wang | Kras g12d inhibitors |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| CN110950886A (zh) * | 2019-12-13 | 2020-04-03 | 苏州莱克施德药业有限公司 | 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法 |
| KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
| US12286431B2 (en) | 2020-09-11 | 2025-04-29 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (de) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidin-pan-kras-hemmer |
| JP2024538851A (ja) * | 2021-10-08 | 2024-10-23 | ブライズ セラピューティクス，インコーポレイテッド | がん治療のための小分子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| DE2757925A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| WO2000055143A1 (en) * | 1999-03-17 | 2000-09-21 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
-
2001
- 2001-12-17 AT AT01985417T patent/ATE295362T1/de not_active IP Right Cessation
- 2001-12-17 MX MXPA03005854A patent/MXPA03005854A/es active IP Right Grant
- 2001-12-17 CA CA002432578A patent/CA2432578C/en not_active Expired - Fee Related
- 2001-12-17 EP EP01985417A patent/EP1363899B1/de not_active Expired - Lifetime
- 2001-12-17 KR KR1020037008921A patent/KR100554813B1/ko not_active Expired - Fee Related
- 2001-12-17 JP JP2002554677A patent/JP4031363B2/ja not_active Expired - Fee Related
- 2001-12-17 BR BR0116662-0A patent/BR0116662A/pt not_active IP Right Cessation
- 2001-12-17 CN CNB018217133A patent/CN1237060C/zh not_active Expired - Fee Related
- 2001-12-17 ES ES01985417T patent/ES2241891T3/es not_active Expired - Lifetime
- 2001-12-17 WO PCT/EP2001/014885 patent/WO2002053558A1/en not_active Ceased
- 2001-12-17 DE DE60110844T patent/DE60110844T2/de not_active Expired - Fee Related
- 2001-12-27 PA PA20018536001A patent/PA8536001A1/es unknown
- 2001-12-27 PE PE2001001308A patent/PE20020735A1/es not_active Application Discontinuation
- 2001-12-28 UY UY27109A patent/UY27109A1/es not_active Application Discontinuation
- 2001-12-28 AR ARP010106092A patent/AR035775A1/es unknown
-
2003
- 2003-06-28 ZA ZA200305038A patent/ZA200305038B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002053558A1 (en) | 2002-07-11 |
| EP1363899A1 (de) | 2003-11-26 |
| JP2004519454A (ja) | 2004-07-02 |
| MXPA03005854A (es) | 2003-09-10 |
| CN1484640A (zh) | 2004-03-24 |
| PE20020735A1 (es) | 2002-08-21 |
| CA2432578A1 (en) | 2002-07-11 |
| JP4031363B2 (ja) | 2008-01-09 |
| KR100554813B1 (ko) | 2006-02-22 |
| BR0116662A (pt) | 2003-09-23 |
| KR20030063490A (ko) | 2003-07-28 |
| DE60110844D1 (de) | 2005-06-16 |
| PA8536001A1 (es) | 2002-08-29 |
| CA2432578C (en) | 2008-04-01 |
| UY27109A1 (es) | 2002-07-31 |
| ES2241891T3 (es) | 2005-11-01 |
| ZA200305038B (en) | 2004-09-27 |
| EP1363899B1 (de) | 2005-05-11 |
| CN1237060C (zh) | 2006-01-18 |
| DE60110844T2 (de) | 2006-01-12 |
| AR035775A1 (es) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60110844D1 (de) | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten | |
| DE60225563D1 (de) | 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate | |
| EP1536291A4 (de) | Entfernungslösung | |
| ATE402148T1 (de) | Substituierte pyridinylamine | |
| DK3473251T3 (da) | Nikotin-cellulose-kombination | |
| DE60207815D1 (de) | 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden | |
| ATE376549T1 (de) | Pyrrolopyridazin derivate | |
| DK1358165T3 (da) | Imidazolderivater | |
| NO20044046L (no) | Substituerte hydroksyetylaminer | |
| DE602004024770D1 (de) | Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
| DE50206892D1 (de) | Substituierte imidazotriazinone | |
| DE60105020D1 (de) | 6-phenylpyrrolopyrimidindion derivate | |
| EP1657477A4 (de) | Abstandsstückspreizer | |
| EE200300447A (et) | Asendatud bensofuraan-2-karboksamiidide derivaadid | |
| DK1373228T3 (da) | Substituerede fluoralkoxyphenylsulfonylurinstoffer | |
| ATE496887T1 (de) | Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide | |
| DE60137209D1 (de) | Kaltfräsvorrichtung | |
| ATE435197T1 (de) | Substituierte 4-aminocyclohexanole | |
| DE60215804D1 (de) | 4-aminopyrimidine derivate | |
| ATE382601T1 (de) | Substituierte 4-aminocyclohexanolderivate | |
| ATE496034T1 (de) | Phtalazinon derivate | |
| DE60208612D1 (de) | Herzschrittmacher | |
| FI20030525A0 (fi) | Suuntaajavälineiden suojauskokoonpano | |
| ATE269316T1 (de) | 2-phenylpyran-4-on derivate | |
| ATE350379T1 (de) | Substituierte benzdioxepine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1363899 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |